ABSI — Recent News Coverage

All news mentioning ABSI in ESEN's AI-graded feed

News stories with ABSI as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on ABSI. See /coverage/ABSI for the 30-day aggregate.

9 articles Updated: 2026-06-25 08:33 UTC Filter: Ticker: $ABSI
SEEKINGALPHA.COM · 2026-06-24 NEUTRAL BULLISH CORR0.42

Absci: Eli Lilly Backs Alopecia Data With Funding, But Risks Remain (NASDAQ:ABSI)

$ABSI $LLY
◈ ESEN AI
ABSI secured a $100M equity investment from Eli Lilly, catalyzing a 30% single-day rally. The funding validates early-stage alopecia program data from Phase 1 trials, demonstrating safety and pharmacokinetic (PK) profil…
RTTNEWS.COM · 2026-06-24 HIGH BULLISH CORR0.72

Absci Corp Stock Rises 18% After Positive Phase 1 Data For AI-Designed Drug Candidate

$ABSI
◈ ESEN AI
ABSI delivered an 18.8% single-session rally following interim Phase 1 clinical readout for ABS-201, an AI-designed antibody targeting prolactin receptor dysfunction. The magnitude of the move reflects biotech sentiment…
RTTNEWS.COM · 2026-06-24 LOW BULLISH CORR0.45

6 Biotech Stocks That Delivered Stunning Gains: INBX +700%, PVLA +500%, MBX +300%, ABSI +200% & More

$INBX $PVLA $MBX $ABSI
◈ ESEN AI
This article highlights retrospective performance analysis of select biotech equities, focusing on INBX, PVLA, MBX, and ABSI among others. The headline presents extreme historical returns (+700% to +200%) without provid…
MARKETS.BUSINESSINSIDER.COM · 2026-06-24 NEUTRAL BULLISH CORR0.35

Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors

$ABSI $LLY
◈ ESEN AI
Absci Corporation has announced a $100 million underwritten equity offering with participation from institutional and strategic investors including Eli Lilly & Company, Adage Capital, BVF Partners, Columbia Threadneedle…
MARKETS.BUSINESSINSIDER.COM · 2026-06-24 NEUTRAL BULLISH CORR0.35

Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)

$ABSI
◈ ESEN AI
Absci (ABSI) reported positive interim Phase 1 data for ABS-201, a novel prolactin receptor-targeting antibody. The candidate demonstrated favorable safety tolerability across all blinded single ascending dose cohorts, …
INSIDERMONKEY.COM · 2026-06-21 LOW NEUTRAL CORR0.35

Is Absci Corporation (ABSI) A Good Stock To Buy Now?

$ABSI
◈ ESEN AI
ABSI is positioned as a potential acquisition candidate within the synthetic biology and antibody design space, with bulls citing proprietary AI-driven protein engineering capabilities as a competitive moat. The thesis …
FINANCE.YAHOO.COM · 2026-06-21 LOW NEUTRAL CORR0.15

Is Absci Corporation (ABSI) A Good Stock To Buy Now?

$ABSI
◈ ESEN AI
ABSI is a clinical-stage biopharmaceutical entity focused on leveraging artificial intelligence and synthetic biology to accelerate drug discovery workflows. The article presents a bullish thesis circulating among retai…
INSIDERMONKEY.COM · 2026-06-16 NEUTRAL BULLISH CORR0.42

Leerink Starts Coverage on Absci Corporation (ABSI)

$ABSI
◈ ESEN AI
Leerink Partners initiated equity research coverage on ABSI with an Outperform rating and a $12 price target, representing a positive market signal for the synthetic biology platform company. This is a standard catalyst…
INSIDERMONKEY.COM · 2026-06-14 NEUTRAL BULLISH CORR0.72

8 Best Genomics Stocks to Buy According to Analysts

$NTRA $ABSI
◈ ESEN AI
The announcement of a five-year AI collaboration between Google DeepMind, Google.org, and the Wellcome Sanger Institute signals accelerating institutional capital commitment to genomics innovation. This partnership vali…
EXPLORE OTHER FILTERS